Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

DDR is a promising arena for the development of precision ... enables rapid configuration of biomarkers across the entire landscape of cancer drug targets, including DDR. Trained on hundreds ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

This investigational drug is being evaluated both as ... noted the critical need for predictive biomarkers in DDR therapy development. The Genialis Supermodel, which has been instrumental in ...

Bioanalytical Testing Services Market size is expected to reach USD 9.0 billion by 2033, achieving a compound annual growth rate (CAGR) of 9.8%.

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.